Results 131 to 140 of about 1,098,931 (194)

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges. [PDF]

Ann Hematol
Wang Y, Zhang Y, Liu J, Jiang Y, Li J, Shi W.   +5 more
europepmc   +1 more source

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. [PDF]

Blood Adv
Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV.   +16 more
europepmc   +1 more source

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]

CPT Pharmacometrics Syst Pharmacol
Demin O, Ou Y, Kolesova G, Shchelokov D, Stepanov A, Musatova V, Sahasranaman S, Zhao Y, Liu X, Tang Z, Hanley WD.   +10 more
europepmc   +1 more source

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. [PDF]

J Allergy Clin Immunol
Lin EV, Arce B, Alvarez-Arango S, Dispenza MC.   +3 more
europepmc   +1 more source

Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]

Ann Hematol
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc   +1 more source

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. [PDF]

Discov Oncol
Hays P.
europepmc   +1 more source

Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. [PDF]

J Manag Care Spec Pharm
Fitzgerald L, Ghosh S, Khan W, Bokun A, Lax A, Mu F, Cook EE, Chen J, Chen G, Wu E, Lin Y, Shi L, Qureshi ZP, Graf SA.   +13 more
europepmc   +1 more source

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction. [PDF]

Br J Haematol
Lin C, Anderson CE, Scobie MR, Rodgers TD, Kelley MJ, Friedman DR.   +5 more
europepmc   +1 more source

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database. [PDF]

Cardiooncology
Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O'Quinn RP.   +5 more
europepmc   +1 more source